Magazine Article | October 30, 2020

Companies To Watch: Ridgeback Biotherapeutics

Source: Life Science Leader

By Wayne Koberstein, Executive Editor, Life Science Leader
Follow Me On Twitter @WayneKoberstein

Pitting new and potent antivirals versus COVID, Ebola, and other coronaviruses

SNAPSHOT

Ridgeback Biotherapeutics is a private company developing antivirals for untreated and pandemic diseases, with support from partnerships and public funding. It is currently partnering with Merck in Phase 2 development of a ribonucleoside analog, coded MK-4482, an oral drug for treating COVID-19 infection by inhibiting viral replication. Another lead product, ansuvimab, is under priority review by the FDA for treating Ebola.

access the Magazine Article!

Get unlimited access to:
Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Life Science Leader? Subscribe today.

Subscribe to Life Science Leader X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.

or

Subscribe to Life Science Leader

Please tell us more about you so that we can customize our newsletters to your specific interests: